title: Antibiotic therapy of early European Lyme borreliosis and acrodermatitis chronica atrophicans.
abstract: In a study on 121 consecutive patients with erythema migrans, 65 patients obtained oral penicillin, 36 tetracyclines, and 20 amoxicillin-clavulanic-acid. Follow-up was carried out for a median of 29, 17, and 7 months, respectively. In another limited trial on 29 patients with acrodermatitis chronica atrophicans (ACA), 14 patients received oral penicillin, 9 parenteral penicillin, and 6 tetracyclines. There was no statistically significant difference among treatment groups in both therapeutic trials, with the exception of different follow-ups due to the nonrandomized study design and different occurrence of the Jarisch-Herxheimer reaction in patients with erythema migrans. Later extracutaneous manifestations developed in 27% of the patients with erythema migrans and in 47% of the patients with ACA despite antibiotic therapy. We could not prove the superiority of any antibiotic tested in either early or late European Lyme borreliosis.
authors.affiliation: Department of Microbiology, University of Munich, Federal Republic of Germany.
authors.forename: K
authors.initials: K
authors.lastname: Weber
authors.forename: V
authors.initials: V
authors.lastname: Preac-Mursic
authors.forename: U
authors.initials: U
authors.lastname: Neubert
authors.forename: R
authors.initials: R
authors.lastname: Thurmayr
authors.forename: P
authors.initials: P
authors.lastname: Herzer
authors.forename: B
authors.initials: B
authors.lastname: Wilske
authors.forename: G
authors.initials: G
authors.lastname: Schierz
authors.forename: W
authors.initials: W
authors.lastname: Marget
mesh_terms: D000169:Acrodermatitis / Q000188:drug therapy / Q000209:etiology*; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic / Q000032:analysis; D000907:Antibodies, Bacterial / Q000032:analysis; D001898:Borrelia / Q000302:isolation & purification; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004890:Erythema / Q000188:drug therapy / Q000209:etiology / Q000382:microbiology; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D007075:Immunoglobulin M / Q000032:analysis; D008193:Lyme Disease / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D008875:Middle Aged
chemical_list: D000900:Anti-Bacterial Agents; D000888:Antibodies, Anti-Idiotypic; D000907:Antibodies, Bacterial; D007074:Immunoglobulin G; D007075:Immunoglobulin M